TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04345237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training
Study: NCT02220738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-957
Description: ABT-957 administered twice-daily for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-957
Description: Placebo for ABT-957 administered twice-daily for 7 days
Study: NCT03134144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Chairless Chair
Description: One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
Study: NCT00198666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Elemental Zinc
Study: NCT01272388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
Study: NCT02805153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Study: NCT01158235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109
Description: 1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
Study: NCT00400023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.~During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FT
Description: During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
Study: NCT04200651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic Insert
Description: DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
Study: NCT01820143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Study: NCT04024046

Intervention type: DIETARY_SUPPLEMENT
Intervention: Uqora
Description: Participants will receive 1 Placebo Drink-Mix and 2 Placebo Capsules Daily

Intervention type: DIETARY_SUPPLEMENT
Intervention: Group1
Description: Participants will receive 1 Uqora Drink-Mix and 2 Placebo Capsules Daily

Intervention type: DIETARY_SUPPLEMENT
Intervention: Group 2
Description: Participants will receive 1 Uqora Drink-Mix and 2 Uqora Capsules Daily
Study: NCT04537078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duphaston
Description: will be used for pituitary suppression in the first arm:20 mg/day will be started from the first day of the ovulation induction in the follicular phase and in the luteal phase will be started the next day after oocyte pickup at 20 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin
Description: will be used for controlled ovarian hyperstimulation in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin
Description: will be used for controlled ovarian hyperstimulation in both arms
Study: NCT03590067

Intervention type: OTHER
Intervention: Questionnaire
Description: The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian

Intervention type: OTHER
Intervention: Questionnaire
Description: The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
Study: NCT03348800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental anesthesia
Description: A tooth extraction will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental anesthesia
Description: A tooth extraction will be performed
Study: NCT02835209

Intervention type: OTHER
Intervention: Work of breathing during SBT
Description: Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
Study: NCT03205345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan (25 mg)
Description: 25 mg emricasan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan (5 mg)
Description: 5 mg emricasan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02665624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna and stewed apricot juice
Description: comparison of bowel cleansing and patient comfort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna alone
Description: comparison of bowel cleansing and patient comfort.
Study: NCT04458376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help program
Description: The program is divided into six short weekly lessons providing information about chronic dizziness and vestibular rehabilitation, and demonstrating the exercises by video. The program is freely available in the Norwegian electronic handbook for physicians (NEL). The participants in the study will receive the internet address after inclusion in the study.
Study: NCT04315428

Intervention type: BEHAVIORAL
Intervention: swaddling
Description: The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed

Intervention type: BEHAVIORAL
Intervention: no swaddling
Description: The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
Study: NCT00647452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate Intensity Exercise (50 % af VO2max) for 90 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
Study: NCT04515745

Intervention type: BEHAVIORAL
Intervention: Intensive lifestyle intervention (ILI)
Description: Lifestyle intervention focused on weight loss through diet and physical activity

Intervention type: BEHAVIORAL
Intervention: Diabetes support and education (DSE)
Description: Behavioral intervention focused on diabetes support and education
Study: NCT04639752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom´s Supporting Mom
Description: A preventive peer consultation intervention for Postpartum Depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual
Description: Referral to treatment in the community, clinical monitoring
Study: NCT01412398

Intervention type: DRUG
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Description: Patients in CAPD who have received Fosrenol for hyperphosphatemia
Study: NCT04454125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AQI intervention
Description: The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
Study: NCT02645578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right median nerve stimulation
Description: Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
Study: NCT01304225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal photocoagulation
Description: Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Description: Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Description: Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
Study: NCT02962622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
Study: NCT00814359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Magic Mouthwash Plus Sucralfate
Description: Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% Benzydamine HCl
Description: Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
Study: NCT03934944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phone application
Description: Weekly foot alerts and educational video

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual routine of diabetic foot education
Study: NCT03944499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS-1502
Description: Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV.
Study: NCT02299674

Intervention type: OTHER
Intervention: Level overground ambulation
Study: NCT03235531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
Study: NCT04984980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
Description: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
Study: NCT03235531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
Study: NCT00096200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT04537078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrotide Injectable Product
Description: will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle \>18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle \>18 mm in diameter in the first cycle only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle \>18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle \>18 mm in diameter in the first cycle only.
Study: NCT00096200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study: NCT03346759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon A
Description: 24 Tampax Pearl Regular Tampons for use during a single menstrual period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon A
Description: 24 Tampax Pearl Regular Tampons for use during a single menstrual period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon B
Description: 24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon B
Description: 24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
Study: NCT02008383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily.
Study: NCT03269812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic assisted pull-through oeration
Description: Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic assisted pull-through oeration
Description: Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
Study: NCT02789787

Intervention type: PROCEDURE
Intervention: Maxillary Protraction
Description: Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate.

Intervention type: PROCEDURE
Intervention: Orthognathic Surgery
Description: The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
Study: NCT00323635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tolterodine
Description: tablet, 4 mg, daily, 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine
Description: tablet, 4 mg, daily, 1 month
Study: NCT02580201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container.